[目的]观察CIK细胞免疫治疗对晚期肾癌患者免疫功能的影响,分析淋巴细胞亚群与血清胆固醇的相关性。[方法]选取晚期肾癌患者36例,其中20例在常规治疗措施的基础上联合应用CIK细胞免疫方法进行治疗,16例为常规治疗,监测两组患者外周血中总T细胞(CD3~+)、总B细胞(CD3-CD19~+)、NK细胞(CD3~-CD16~+CD56~+)辅助诱导T细胞(CD3~+CD4~+)、CD4/CD8比值等免疫功能指标,并进行统计学分析。[结果 ]联合CIK治疗的肾癌患者外周血中抑制/细胞毒性T细胞从24.41%±8.61%上升到44.41%±19.29%、辅助/诱导T细胞从41.09%±11.52%下降为30.15%±13.96%、CD4/CD8比值从1.95±0.95下降到0.93±0.67、CD3~+HLA-DR~+细胞从15.31%±10.40%上升为45.77%±31.94%、CD8~+HLA-DR~+细胞从10.07%±6.93%上升到36.12%±25.89%,与常规治疗组相比有统计学差异。NK细胞比率与血清总胆固醇、低密度脂蛋白和载脂蛋白B成负相关(r=-0.450,P=0.014;r=-0.469,P=0.010;r=-0.406,P=0.029)。[结论]采用CIK细胞免疫治疗能有效提高转移性肾癌患者的细胞免疫功能,血清胆固醇代谢可能参与调节肿瘤免疫。 [Objective] To observe the effect of CIK cell immunotherapy on immune function in patients with advanced renal cell carcinoma and to analyze the correlation between lymphocyte subsets and serum cholesterol. [Methods] Thirty-six patients with advanced renal cell carcinoma were selected, of whom 20 were treated with CIK cell-based immunotherapy on the basis of routine treatment and 16 were routinely treated. The levels of total T cells (CD3 + ), Total B cells (CD3-CD19 ~ +) and NK cells (CD3 ~ -CD16 ~ + CD56 ~ +) help to induce immune function indexes such as T cell (CD3 ~ + CD4 ~ +) and CD4 / CD8 ratio Statistical analysis. [Results] The levels of suppressor / cytotoxic T cells in peripheral blood from CIK-treated patients increased from 24.41% ± 8.61% to 44.41% ± 19.29%, and the number of helper / induced T cells decreased from 41.09% ± 11.52% to 30.15% ± 13.96 The percentage of CD4 / CD8 decreased from 1.95 ± 0.95 to 0.93 ± 0.67, and the percentage of CD8 ~ + HLA-DR ~ + cells increased from 15.31% ± 10.40% to 45.77% ± 31.94% % ± 6.93% to 36.12% ± 25.89%, which is statistically significant compared with the conventional treatment group. NK cell ratio was negatively correlated with serum total cholesterol, low density lipoprotein and apolipoprotein B (r = -0.450, P = 0.014; r = -0.469, P = 0.010; r = -0.406, P = 0.029). [Conclusion] CIK cell immunotherapy can effectively improve cellular immune function in patients with metastatic renal cell carcinoma, serum cholesterol metabolism may be involved in the regulation of tumor immunity.